Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
21 April 2021 | Story Financial Aid

Dear Student

Please take note that the NSFAS appeals process is now open.

FIRST TIME AND NEW APPLICANTS

First time1 and new applicants2 for NSFAS funding for 2021 whose applications were rejected by NSFAS must submit their appeal electronically on the MyNSFAS portal. Financial Aid offices may not accept manual forms for this group of students and may not submit manual appeals for this group to NSFAS. You will be able to track your status on the MyNSFAS portal.

SENIOR RETURNING/CONTINUING STUDENTS

Please see appeal form attached.

The following process is ONLY applicable to NSFAS returning/continuing students and exclude first time
and new applicants for NSFAS funding in 2021.

The following documents must be submitted from your “ufs4life” email address for your appeal to be
considered:
  • 1. Completed and signed appeal form attached herewith.
  • 2. Ensure that the relevant box indicating the reason for your appeal is checked.
  • 3. Signed motivation
  • 4. Supporting documents (e.g. Medical certificates, death certificate etc.) Your appeal can
  • unfortunately not be considered in the absence of documentation in support of your reason and
  • motivation for the appeal.
Please note that NSFAS confirmed that you cannot appeal if you exceeded the N+ period. You can only
submit an appeal for one of the reasons provided on the appeal form.

Please submit the abovementioned required documents as one single combined attachment in legible 
PDF format to your campus specific e-mail address below:
Bloemfontein Campus – NSFASAppealsBfn@ufs.ac.za
Qwaqwa Campus – NSFASAppealsQQ@ufs.ac.za
The closing date for submission of appeals is 30 April 2021 at 16:00 and no appeals will be accepted after
this date.

Issued by

Financial Aid

 

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept